Clinical Trials Logo
  1. Home
  2. Agitation,Psychomotor
  3. NCT03208452

The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation

Agitation,Psychomotor Clinical Trial

Official title:
The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation After Pediatric Ophthalmic Surgery

Clinical Trial Summary

This study designed to evaluate the correlation between the effect of intraoperative magnesium sulfate infusion and the incidence of emergence agitation after pediatric ophthalmic surgery

Clinical Trial Description

Emergence agitation (EA) is a frequent postoperative complication in pediatric patients after general anesthesia. There are several suggested causes of EA and pain has been considered one of them. Magnesium is an N-methyl-D-aspartate (NMDA) receptor antagonist and increasingly used as an analgesic-adjuvant. We evaluate the Pediatric Anesthesia Emergence Delirium (PAED) Scale to investigate whether the intraoperative infusion of magnesium sulfate reduces the incidence of EA in pediatric patients who undergo ophthalmic outpatient surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03208452
Study type Interventional
Source Seoul National University Bundang Hospital
Contact
Status Completed
Phase Phase 4
Start date March 19, 2017
Completion date December 19, 2018
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03110900 - Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation Phase 4
Completed NCT05272501 - CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial N/A
Completed NCT06041646 - Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Phase 4
Completed NCT06217146 - A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia. N/A
Recruiting NCT05543681 - IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's Phase 2
Recruiting NCT03513549 - Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Not yet recruiting NCT05612711 - Dronabinol for Agitation in Dementia Crossover Trial Phase 2
Recruiting NCT04957238 - Physical Restraints in Intensive Care Unit Patients N/A
Terminated NCT03899506 - Olanzapine Versus Midazolam for Agitation
Completed NCT03211897 - Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation N/A
Recruiting NCT05783505 - A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use N/A
Completed NCT04053426 - Agitation Follow up After Introduction of a New Patient Care Algorithm
Completed NCT03226522 - Addressing Dementia Via Agitation-Centered Evaluation Phase 2/Phase 3
Recruiting NCT03926520 - Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) N/A
Recruiting NCT04075435 - Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia Early Phase 1
Completed NCT04276883 - Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder Phase 3
Completed NCT04797715 - Assessing Clinical Outcomes in Alzheimer's Disease Agitation Phase 3
Completed NCT04251910 - Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Phase 1/Phase 2
Recruiting NCT05765162 - Safe Brain Initiative, Operationalizing Precision Anaesthesia